TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, together with specialty biotech company, Cellestia Biotech AG (“Cellestia”), today announced that the companies will jointly invest up to USD 34 million in the newly formed U.S.-based biotechnology company, Anciata Therapeutics, Inc. (“Anciata”). TVM will invest with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”) and will provide strategic advice to Anciata, with Dr. Ivan T. Shaw, Principal, joining the Board of Directors and Dr. Marc Rivière, General Partner and Chief Medical Officer to the Fund, serving as a Board Observer. Robert Karsunky will also join the Board of Directors to represent Cellestia. Anciata is the 11th early-stage or project-focused company (PFC) investment for TVM LSI II.
TVM Capital Life Science and Anciata Therapeutics have the option to engage with ExploR&D, a separate research and development unit within Eli Lilly and Company that provides early development services.
Anciata Therapeutics plans to develop to clinical proof of concept IPX-2017, a novel, potentially first-in-class therapeutic candidate with the potential to treat certain types of difficult-to-manage autoimmune disorders.
